Semaglutide (Novo Nordisk) in Localized Prostate Carcinoma: NCT07727473 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Early Phase 1
Clinical phase
Not yet recruiting
Recruitment status
20
Planned enrollment
2028-05-01
Primary-completion proxy
Executive view
NCT07727473 evaluates Semaglutide (Novo Nordisk) in Localized Prostate Carcinoma. The disclosed sponsor is Banner Health, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Change in Caspase-3 (CC3) activation between baseline biopsy and radical prostatectomy specimen, assessed over Baseline (pre-treatment biopsy) through radical prostatectomy, assessed up to 6 months.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07727473 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Localized Prostate Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for Semaglutide (Novo Nordisk), while Company & Deal Intelligence MCP organization_fetch was queried for Banner Health.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07727473 | Semaglutide (Novo Nordisk) | Early Phase 1 / Not yet recruiting | Banner Health | United States | Change in Caspase-3 (CC3) activation between baseline biopsy and radical prostatectomy specimen Baseline (pre-treatment biopsy) through radical prostatectomy, assess… | 2028-05-01 |
| NCT07717099 | Radium Ra-223 Dichloride | Phase 2 / Not yet recruiting | Sponsor not reported | Spain | Treatment compliance Throughout the study treatment period, approximately 6 months | 2029-12-01 |
| NCT07683182 | Prilocaine Hydrochloride | Not Applicable / Active, not recruiting | Marmara University | Turkey | Pain During Transperineal Prostate Biopsy During the biopsy procedure | 2026-06-01 |
| NCT07677566 | Darolutamide | Phase 4 / Not yet recruiting | Nanjing Drum Tower Hospital | China | pCR + MRD Screening, End of Neoadjuvant Treatment( 12 weeks after baseline) | 2027-07-01 |
| NCT07674771 | Gallium GA-68 Gozetotide | Early Phase 1 / Not yet recruiting | The University of Texas Southwestern Medical Center | United States | Reduction in PSMA-positive TTV 1 YEAR | 2029-06-15 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07727473 is a Early Phase 1, not yet recruiting study with 20 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Change in Caspase-3 (CC3) activation between baseline biopsy and radical prostatectomy specimen” over “Baseline (pre-treatment biopsy) through radical prostatectomy, assessed up to 6 months.” The retrieved endpoint description is: Measured via immunohistochemistry on prostate biopsy tissue and radical prostatectomy specimens; change assessed between pre-treatment biopsy and surgical specimen..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 20 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Localized Prostate Carcinoma. These records do not establish direct evidence for NCT07727473 unless the registration number matches.
Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Usin…
Phase 2; n=223; PFS(Median): Hazard Ratio (HR) = 0.29(95% CI, 0.20 - 0.40), P-Value = <0.001; PFS(Median) = 14.3 Months (95% Confidence Interval, 11.20 - 17.38) Source: https://clinicaltrials.gov/ct2/show/results/NCT05059236
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients W…
Phase 3; n=1012; rPFS(Median) = 33.2 Months (95% Confidence Interval, 25.8 - 44.2); rPFS(Median): Hazard Ratio (HR) = 0.81(95% CI, 0.66 - 0.98), P-Value = 0.034 Source: https://clinicaltrials.gov/ct2/show/results/NCT04493853
Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy
Phase 4; n=10; Change in Cardiovagal Baroreflex Sensitivity(Mean) = 0.56 ms/mmHg (Standard Deviation, 1.48); Change in Cardiovagal Baroreflex Sensitivity(Mean) = -4.82 ms/mmHg (Standard Deviation, 1.84) Source: https://clinicaltrials.gov/ct2/show/results/NCT05700903
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Semaglutide (Novo Nordisk) is indexed as Recombinant polypeptide with GLP-1R biology and a global stage of Approved. The asset profile lists Novo Nordisk A/S as an originator or developer.
Banner Health is indexed in United States with the website https://www.bannerhealth.com. Banner Health operates as a nonprofit health care system in the United States. The company offers hospital care, home care, hospice care, The record lists 1 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Semaglutide (Novo Nordisk) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07727473
Protocol source: https://clinicaltrials.gov/study/NCT07727473
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
Semaglutide (Novo Nordisk) in Localized Prostate Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Change in Caspase-3 (CC3) activation between baseline biopsy and radical prostatectomy specimen and 2028-05-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
